


# The Evaluation<sup>®</sup> platform

Get inspired: cases

The Evaluation<sup>®</sup> technology combines features that allow the development of next generation immunoassays. *Get inspired* by some of the cases that were built to demonstrate the platform's capabilities




## CASE: Cytokines

At MyCartis, we have built a **multiplex** cytokine assay to measure IL-1 $\beta$ , IL-2, IL-4, IL-6, IL-8, IL-10, TNF- $\alpha$  and GM-CSF.

This **highly specific and highly sensitive** assay can be run in ~90 minutes on matrices like CSF, plasma and serum. Using this assay, **robust** results are generated on the intra-cartridge replicate level, on the inter-cartridge level as well as the inter-platform level.


### Sensitivity

Low- to sub-ng/ml sensitivity




### IL-2

single instrument; 3 cartridges




## CASE: Diagnosis in Alzheimer's disease



Amyloid-beta (A $\beta$ ) peptides and tau proteins in cerebrospinal fluid (CSF) are often used as biomarkers for Alzheimer's disease. Natural concentration ranges of these biomarkers are very different, hence they are typically measured individually. MyCartis has developed a **multiplex** assay on Evaluation to measure A $\beta$ <sub>1-40</sub>, A $\beta$ <sub>1-42</sub> and total tau concentrations in CSF. Thanks to the **broad assay dynamic range** offered by Evaluation<sup>®</sup>, the assay can quantify all these biomarkers in a single sample dilution.

Our **multiplex** assay shows that the multiparameter approach of measuring A $\beta$ <sub>1-42</sub>/A $\beta$ <sub>1-40</sub> ratio has better clinical performance on discriminating Alzheimer's disease from the healthy population than using A $\beta$ <sub>1-42</sub> or total tau alone.


## CASE: Auto-immune disease



At MyCartis, we have built a robust **multiplex** assay to quantify IgG immunoglobulins in blood of patient with suspected autoimmune disease. This assay consumes just **1ul of plasma** and provides multiplex results on 16 samples within **20 minutes**.

With these assay characteristics, the Evaluation® platform is capable of analyzing more samples than the typical gold standard platform in a medium-size clinical laboratory. By building comprehensive panels, repetitive and sequential testing algorithms are avoided.

## CASE: Immune monitoring in food allergy



MyCartis has built a food allergy test to **qualify and quantify** specific endogenous IgE fractions in the **blood** of patients with suspected peanut allergy, without the requirement of fractionation. Next to a broad extract test, individual peanut allergens are included. It is known that sIgE titers do not reflect the phenotypic presentation of an allergic patient upon challenge. Hence, MyCartis has expended its test to also measure the specific allergic immune response, directly from plasma.

## Partnerships

MyCartis provides expert services utilizing its Evaluation<sup>®</sup>. Our service program includes

- MyCartis collaborates with the Life Science industry for biomarker testing and assay development in research, translational and clinical trials.
- MyCartis offers its platform solutions to the CRO's and service labs to provide their customers the best solution in companion diagnostics and assay development needs
- MyCartis looks to partner with biomarker discovery companies who are interested in bringing new biomarkers and assays onto the Evaluation<sup>®</sup> Platform
- MyCartis provides technology access to diagnostic platform and technology companies with the opportunity to use the DMAT<sup>®</sup> technology as a "reader inside" (OEM approach)



MyCartis NV

Industriepark Zwijnaarde 7C

B-9052 Zwijnaarde

Belgium

[www.mycartis.net](http://www.mycartis.net) - [info@mycartis.net](mailto:info@mycartis.net)

+32 9 2779 888